Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

RELIEF THERAPEUTICS Holding stock price, quote, forecast and news

RLF.SW
CH0100191136
A1H80W

Price

2.15 CHF
Today +/-
+0.16 CHF
Today %
+7.23 %
P

RELIEF THERAPEUTICS Holding stock price

CHF
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the RELIEF THERAPEUTICS Holding stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the RELIEF THERAPEUTICS Holding stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the RELIEF THERAPEUTICS Holding stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze RELIEF THERAPEUTICS Holding's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

RELIEF THERAPEUTICS Holding Stock Price History

DateRELIEF THERAPEUTICS Holding Price
9/6/20242.15 CHF
9/5/20242.00 CHF
9/4/20241.83 CHF
9/3/20241.56 CHF
9/2/20241.70 CHF
8/30/20241.17 CHF
8/29/20241.08 CHF
8/28/20241.06 CHF
8/27/20241.07 CHF
8/26/20241.06 CHF
8/23/20241.07 CHF
8/22/20241.09 CHF
8/21/20241.10 CHF
8/20/20241.10 CHF
8/19/20241.10 CHF
8/16/20241.10 CHF
8/15/20241.10 CHF
8/14/20241.11 CHF
8/13/20241.10 CHF
8/12/20241.12 CHF

RELIEF THERAPEUTICS Holding Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into RELIEF THERAPEUTICS Holding, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by RELIEF THERAPEUTICS Holding from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects RELIEF THERAPEUTICS Holding’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of RELIEF THERAPEUTICS Holding. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into RELIEF THERAPEUTICS Holding’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing RELIEF THERAPEUTICS Holding’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on RELIEF THERAPEUTICS Holding’s growth potential.

RELIEF THERAPEUTICS Holding Revenue, EBIT and net profit per share

DateRELIEF THERAPEUTICS Holding RevenueRELIEF THERAPEUTICS Holding EBITRELIEF THERAPEUTICS Holding Net Income
2028e1.17 B CHF1.02 B CHF920.41 M CHF
2027e518.84 M CHF406.95 M CHF357.7 M CHF
2026e643.6 M CHF90.1 M CHF58.21 M CHF
2025e76.26 M CHF15.05 M CHF11,123.97 CHF
2024e44.15 M CHF-4.01 M CHF-11,123.97 CHF
20236.03 M CHF-19.53 M CHF-98.18 M CHF
20226.08 M CHF-25.62 M CHF-50.79 M CHF
20213.32 M CHF-33.56 M CHF-34.71 M CHF
20200 CHF-20.29 M CHF-7.83 M CHF
20190 CHF-862,000 CHF-7.46 M CHF
2018565,000 CHF-500,000 CHF-436,000 CHF
20170 CHF-1.74 M CHF-2.89 M CHF
201615,000 CHF-1.93 M CHF-16.83 M CHF
20150 CHF-81,000 CHF-81,000 CHF
20140 CHF-6.14 M CHF-10.78 M CHF
201320.8 M CHF-11.52 M CHF-12.22 M CHF
20120 CHF-6.18 M CHF-6.48 M CHF
20110 CHF-11.99 M CHF-59.17 M CHF
2010390,000 CHF-18.75 M CHF-19.4 M CHF
200913.74 M CHF-10.37 M CHF-12.21 M CHF
200814.55 M CHF-9.17 M CHF-9.4 M CHF
200714.83 M CHF-1.73 M CHF-1.61 M CHF
20062.48 M CHF-6.14 M CHF-7.22 M CHF

RELIEF THERAPEUTICS Holding Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B CHF)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M CHF)EBIT (B CHF)EBIT MARGIN (%)NET INCOME (M CHF)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
2006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
00.010.010.010000.02000000000.010.010.040.080.640.521.17
-600.00--7.14------------100.00-633.3372.73746.05-19.44125.48
-------30.00-------66.6766.6766.67-----
00000006000000024400000
-0.01-0-0.01-0.01-0.02-0.01-0.01-0.01-0.010-0-000-0.02-0.03-0.03-0.02-00.020.090.411.02
-300.00-7.14-64.29-76.92----55.00--------1,100.00-416.67-316.67-9.0919.7414.0078.3887.24
-7-1-9-12-19-59-6-12-100-16-20-7-7-34-50-980058357920
--85.71800.0033.3358.33210.53-89.83100.00-16.67---87.50---385.7147.0696.00---515.52157.70
0.040.10.130.070.070.070.070.170.480.591.271.992.052.10.010.010.010.0100000
-----------------------
Details

Keystats

ⓘ

Revenue and Growth

The RELIEF THERAPEUTICS Holding Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the RELIEF THERAPEUTICS Holding is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M CHF)RECEIVABLES (M CHF)OTHER REC. (M CHF)INVENTORIES (M CHF)OTHER CURRENT LIAB. (M CHF)CURRENT ASSETS (M CHF)TANGIBLE ASSETS (M CHF)LONG-T. INVEST. (k CHF)LONG-T. REC. (k CHF)INTANGIBLE ASSETS (M CHF)GOODWILL (M CHF)OTHER NON-CURRENT ASSETS (M CHF)NON-CURRENT ASSETS (M CHF)TOTAL ASSETS (M CHF)LIABILITIESCOMMON STOCK (M CHF)ADDITIONAL PAID-IN CAPITAL (M CHF)RETAINED EARNINGS (M CHF)OTHER EQUITY (k CHF)UNREAL. GAINS/LOSSES (M CHF)EQUITY (M CHF)LIABILITIES (M CHF)PROVISIONS (M CHF)OTHER SHORT-TERM LIAB. (M CHF)SHORT-TERM DEBTS (M CHF)LONG-TERM DEBT PORTION (M CHF)SHORT-TERM REC. (M CHF)LONG-T. LIAB. (M CHF)DEFERRED TAXES (M CHF)OTHER LIAB. (M CHF)LONG-T. LIABILITIES (M CHF)DEBT (M CHF)TOTAL CAPITAL (M CHF)
200620072008200920102011201220132014201520162017201820192020202120222023
                                   
15.3111.0114.094.632.41.80.330.974.390.010.390.140.270.1338.2544.7619.2414.56
0.532.630.070.090.0900.024.023.250000001.622.041.67
0.393.761.120.680.20.140.31.740.410000000.120.150.17
00000002.680.520000000.390.230.56
0.070.026.33.56.70.430.050.210.6100.220.030.090.138.618.090.931.35
16.317.4221.588.99.392.370.79.629.20.010.620.170.350.2646.8554.9722.5818.3
0.694.731.035.251.130.640.580.842.500.010.010002.542.692.97
00000000000000392000
00000006026.39000000000
59.7956.9854.0551.0747.80.2602.74.89030.830.835.2219.630.8183.64155.953.87
000000030.1319.850000008.667.020.55
00000002.690.080000001.810.610.71
60.4861.7155.0856.3248.930.90.5836.4227.35030.8130.8135.2219.631.19196.65166.2258.09
76.7879.1376.6665.2258.323.271.2846.0436.540.0131.4230.9735.5819.8678.05251.62188.876.39
                                   
0.340.640.650.650.670.690.73.985.756.5519.4720.0720.8921.1432.4744.1356.1656.16
000000000000000207.52215.69214.18
65.863.8568.2856.0851.7-0.23-3.3816.217.4-6.62.770.880.39-6.8434.58-67.38-115.04-212.89
000000000000000255716779
000000000000000000
66.1464.4968.9356.7352.370.46-2.6820.1823.14-0.0522.2420.9521.2814.367.04184.53157.5358.23
00001.511.070.657.594.1200.380.490.120.281.431.71.631.03
7.822.72.893.110.790.870.361.3600000002.142.141.74
2.48.154.325.042.87004.433.170.070.390.530.790.84.3714.214.861.93
00000002.360001.011.051.740.891.251.281.36
0.090.240.190.160.120.552.642.873.2400.8800000.430.820.86
10.3111.097.48.315.292.493.6518.6110.540.071.652.041.962.826.6919.7310.726.91
0.313.530.330.170.270.130.13.230.190000002.592.252.1
00000000.821.2906.477.457.452.744.3125.520.747.37
0.020.01000.360.190.222.741.3901.070.544.880022.269.687.79
0.333.540.330.170.630.320.326.792.8707.547.9912.332.744.3150.3632.6717.25
10.6414.637.738.485.922.813.9725.413.410.079.1910.0314.295.571170.0943.3824.16
76.7879.1276.6665.2158.293.271.2945.5836.550.0131.4230.9735.5819.8678.05254.62200.9182.39
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of RELIEF THERAPEUTICS Holding provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand RELIEF THERAPEUTICS Holding's financial health and stability.

Assets

RELIEF THERAPEUTICS Holding's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that RELIEF THERAPEUTICS Holding must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of RELIEF THERAPEUTICS Holding after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into RELIEF THERAPEUTICS Holding's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M CHF)DEPRECIATION (M CHF)DEFERRED TAXES (M CHF)CHANGES IN WORKING CAPITAL (M CHF)NON-CASH ITEM (M CHF)PAID INTEREST (M CHF)PAID TAXES (M CHF)NET CASH FLOW FROM OPERATING ACTIVITIES (M CHF)CAPITAL EXPENDITURES (M CHF)CASH FLOW FROM INVESTING ACTIVITIES (M CHF)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M CHF)INTEREST INCOME AND EXPENSES (M CHF)NET DEBT CHANGE (M CHF)NET CHANGE IN EQUITY (M CHF)CASH FLOW FROM FINANCING ACTIVITIES (M CHF)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M CHF)TOTAL DIVIDENDS PAID (M CHF)NET CHANGE IN CASH FLOW (M CHF)FREE CASH FLOW (M CHF)SHARE-BASED COMPENSATION (M CHF)
20062007200820092010201120122013201420152016201720182019202020212022
-7-2-9-12-19-59-6-12-100-16-20-7-7-34-50
03333101200000023
00000000000000000
8-4-33-2000-1000000-55
0001147222014106-10217
00000000000000000
00000000000000000
2-3-9-3-16-10-4-8-70-2-100-18-35-24
000-500000000000-130
000-502000000003-30-7
000002000000003-16-7
00000000000000000
130000001-1000000-50
0013014718130300058767
13013014639110300058676
000000200000000-20
00000000000000000
14-43-9-20-10300000431-25
1.77-4.03-10.37-9.09-16.92-10.25-4.65-9.7-8.44-0.03-2.9-1.17-0.62-0.73-18.25-49.43-24.65
00000000000000000

RELIEF THERAPEUTICS Holding stock margins

The RELIEF THERAPEUTICS Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of RELIEF THERAPEUTICS Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for RELIEF THERAPEUTICS Holding.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the RELIEF THERAPEUTICS Holding's sales revenue. A higher gross margin percentage indicates that the RELIEF THERAPEUTICS Holding retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the RELIEF THERAPEUTICS Holding's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the RELIEF THERAPEUTICS Holding's total revenue generated. When comparing the revenue margin year over year, investors can gauge the RELIEF THERAPEUTICS Holding's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the RELIEF THERAPEUTICS Holding. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the RELIEF THERAPEUTICS Holding's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

RELIEF THERAPEUTICS Holding Margin History

RELIEF THERAPEUTICS Holding Gross marginRELIEF THERAPEUTICS Holding Profit marginRELIEF THERAPEUTICS Holding EBIT marginRELIEF THERAPEUTICS Holding Profit margin
2028e71.22 %87.24 %78.8 %
2027e71.22 %78.43 %68.94 %
2026e71.22 %14 %9.04 %
2025e71.22 %19.74 %0.01 %
2024e71.22 %-9.09 %-0.03 %
202371.22 %-323.74 %-1,627.4 %
202279.44 %-421.25 %-835.22 %
202177.42 %-1,010.54 %-1,045.02 %
202071.22 %0 %0 %
201971.22 %0 %0 %
201871.22 %-88.5 %-77.17 %
201771.22 %0 %0 %
201671.22 %-12,886.67 %-112,226.67 %
201571.22 %0 %0 %
201471.22 %0 %0 %
201329.33 %-55.38 %-58.75 %
201271.22 %0 %0 %
201171.22 %0 %0 %
201071.22 %-4,807.69 %-4,974.36 %
200971.22 %-75.47 %-88.86 %
200871.22 %-63.02 %-64.6 %
200771.22 %-11.67 %-10.86 %
200671.22 %-247.58 %-291.13 %

RELIEF THERAPEUTICS Holding Stock Sales Revenue, EBIT, Earnings per Share

The RELIEF THERAPEUTICS Holding earnings per share therefore indicates how much revenue RELIEF THERAPEUTICS Holding has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue RELIEF THERAPEUTICS Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates RELIEF THERAPEUTICS Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of RELIEF THERAPEUTICS Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RELIEF THERAPEUTICS Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

RELIEF THERAPEUTICS Holding Revenue, EBIT and net profit per share

DateRELIEF THERAPEUTICS Holding Sales per ShareRELIEF THERAPEUTICS Holding EBIT per shareRELIEF THERAPEUTICS Holding Earnings per Share
2028e106.05 CHF0 CHF83.57 CHF
2027e47.11 CHF0 CHF32.48 CHF
2026e58.44 CHF0 CHF5.29 CHF
2025e6.92 CHF0 CHF0 CHF
2024e4.01 CHF0 CHF-0 CHF
20230.51 CHF-1.66 CHF-8.35 CHF
20220.58 CHF-2.42 CHF-4.8 CHF
20210.37 CHF-3.74 CHF-3.86 CHF
20200 CHF-3.36 CHF-1.3 CHF
20190 CHF-0 CHF-0 CHF
20180 CHF-0 CHF-0 CHF
20170 CHF-0 CHF-0 CHF
20160 CHF-0 CHF-0.01 CHF
20150 CHF-0 CHF-0 CHF
20140 CHF-0.01 CHF-0.02 CHF
20130.12 CHF-0.07 CHF-0.07 CHF
20120 CHF-0.09 CHF-0.09 CHF
20110 CHF-0.18 CHF-0.86 CHF
20100.01 CHF-0.28 CHF-0.29 CHF
20090.21 CHF-0.16 CHF-0.19 CHF
20080.11 CHF-0.07 CHF-0.07 CHF
20070.14 CHF-0.02 CHF-0.02 CHF
20060.07 CHF-0.17 CHF-0.2 CHF

RELIEF THERAPEUTICS Holding business model

RELIEF THERAPEUTICS Holding SA is a Swiss biotech company that specializes in the research and development of novel therapies for the treatment of serious diseases. The company was founded in 2016 and is based in Geneva. The history of RELIEF THERAPEUTICS began with the discovery of a promising molecule called Aviptadil. Aviptadil is a synthetic peptide derived from the natural hormone VIP (Vasoactive Intestinal Peptide). It has the ability to regulate a variety of biological processes in the body and has shown promise as a therapy for a range of diseases. Since its inception, the company has formed a number of partnerships and collaborations with other companies and research institutions to support its research projects and bring its technology to market. The business model of RELIEF THERAPEUTICS is based on the research and development of innovative therapies for a variety of serious diseases for which there is currently no effective treatment. The company focuses on the research and development of peptides and proteins as a new class of therapeutic agents. RELIEF THERAPEUTICS has several business segments active in drug development. The first segment is the respiratory diseases segment, in which the company utilizes its core expertise in the development of Aviptadil to explore innovative therapies for severe respiratory diseases such as idiopathic pulmonary fibrosis (IPF), acute and chronic respiratory distress syndromes (ARDS/CRDS), and asthma. Another important segment of RELIEF THERAPEUTICS is cancer research. The company is working on the development of new cancer therapies based on Aviptadil, targeting the regulation of tumor growth and metastasis formation. The third segment of the company is pain therapy. Here, RELIEF THERAPEUTICS is working on the development of peptide-based analgesics to alleviate pain in various conditions such as cancer, neuropathic pain, and postoperative pain. RELIEF THERAPEUTICS currently offers several products based on Aviptadil. One of these products is RLF-100, also known as ZYESAMI, a potential drug for the treatment of severe respiratory diseases such as ARDS/CRDS and COVID-19. RLF-100 is an inhalable Aviptadil specifically developed for the treatment of respiratory diseases and has shown high efficacy in clinical studies. Another product from RELIEF THERAPEUTICS is RLF-888, a potential drug for the treatment of neuropathic pain. RLF-888 has been developed as a peptide-based analgesic and has shown promising results in preclinical studies. In 2021, RELIEF THERAPEUTICS acquired a majority stake in APR Applied Pharma Research SA, expanding its product range and business areas. APR is increasingly gaining importance in the acute aplastic pain market and could prove to be an important part of RELIEF THERAPEUTICS' product diversity in the future. Overall, RELIEF THERAPEUTICS has positioned itself as a promising player in the biotech industry and continues to strive to develop innovative therapies for serious diseases to help patients worldwide. RELIEF THERAPEUTICS Holding is one of the most popular companies on Eulerpool.com.

RELIEF THERAPEUTICS Holding SWOT Analysis

Strengths

RELIEF THERAPEUTICS Holding SA possesses several strengths that contribute to its competitive advantage:

  • Strong R&D capabilities and a robust pipeline of potential therapeutics
  • Strong intellectual property portfolio and proprietary technologies
  • Experienced management team with a successful track record in the pharmaceutical industry
  • Strategic partnerships and collaborations with leading research institutions and pharmaceutical companies
  • Strong financial position, enabling investment in research and development

Weaknesses

Despite its strengths, RELIEF THERAPEUTICS Holding SA also faces certain weaknesses that pose challenges to its growth:

  • Dependence on the success of drug development, which carries inherent risks and uncertainties
  • Relatively small market presence compared to larger pharmaceutical companies
  • Highly regulated industry, requiring compliance with strict regulatory guidelines
  • Possible limitations in manufacturing and distribution capabilities

Opportunities

RELIEF THERAPEUTICS Holding SA can capitalize on the following opportunities to expand its market presence:

  • Increasing global demand for innovative and effective therapeutics
  • Expanding partnerships and collaborations to access new markets and technologies
  • Advancements in technology and scientific knowledge, providing new avenues for drug development
  • Growing prevalence of chronic diseases, creating an increased need for therapeutic solutions
  • Emerging markets with growing healthcare infrastructure and rising consumer purchasing power

Threats

RELIEF THERAPEUTICS Holding SA should be aware of the following threats that could impact its business:

  • Intense competition from established pharmaceutical companies and new entrants
  • Stringent regulatory requirements and potential delays in obtaining approvals
  • Uncertainties related to patent protection and potential infringement by competitors
  • Market volatility and economic downturns affecting the affordability and accessibility of therapies
  • Potential adverse effects or challenges in clinical trials and drug development

RELIEF THERAPEUTICS Holding Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

RELIEF THERAPEUTICS Holding historical P/E ratio, EBIT, and P/S ratio.

RELIEF THERAPEUTICS Holding shares outstanding

The number of shares was RELIEF THERAPEUTICS Holding in 2023 — This indicates how many shares 11.752 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue RELIEF THERAPEUTICS Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates RELIEF THERAPEUTICS Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of RELIEF THERAPEUTICS Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RELIEF THERAPEUTICS Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

RELIEF THERAPEUTICS Holding Stock splits

In RELIEF THERAPEUTICS Holding's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for RELIEF THERAPEUTICS Holding.

Eulerpool ESG Scorecard© for the RELIEF THERAPEUTICS Holding stock

Eulerpool World ESG Rating (EESG©)

33/ 100

🌱 Environment

37

👫 Social

30

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

RELIEF THERAPEUTICS Holding list of shareholders

%
Name
Stocks
Change
Date
8.71632 % Armistice Capital LLC960,00003/4/2024
26.23746 % Global Emerging Markets2,889,748012/12/2023
0.70905 % Galfetti (Paolo)78,09478,09412/31/2022
0.46817 % Credit Suisse Funds AG51,56303/31/2024
0.44720 % Zürcher Kantonalbank (Asset Management)49,25402/29/2024
0.44381 % UBS Asset Management (Switzerland)48,88103/31/2024
0.36685 % Credit Suisse Asset Management (Schweiz) AG40,40403/31/2024
0.17637 % Pictet Asset Management Ltd.19,425012/31/2023
0.05680 % BlackRock Advisors (UK) Limited6,25603/31/2024
0.05448 % UBS Asset Management Switzerland AG6,00002/29/2024
1
2
3
4

RELIEF THERAPEUTICS Holding Executives and Management Board

Dr. Raghuram Selvaraju45
RELIEF THERAPEUTICS Holding Chairman of the Board (since 2016)
Compensation 500,000 CHF
Mr. Paolo Galfetti58
RELIEF THERAPEUTICS Holding Chief Operating Officer, Director (since 2021)
Compensation 150,000 CHF
Dr. Patrice Jean52
RELIEF THERAPEUTICS Holding Director
Compensation 150,000 CHF
Dr. Thomas Plitz55
RELIEF THERAPEUTICS Holding Director
Compensation 150,000 CHF
Ms. Michelle Lock55
RELIEF THERAPEUTICS Holding Interim Chief Executive Officer, Director (since 2022)
Compensation 92,473 CHF
1
2

Most common questions regarding RELIEF THERAPEUTICS Holding

What values and corporate philosophy does RELIEF THERAPEUTICS Holding represent?

RELIEF THERAPEUTICS Holding SA represents values and a corporate philosophy rooted in the commitment to provide innovative therapeutic solutions for unmet medical needs. As a reputable pharmaceutical company, RELIEF THERAPEUTICS focuses on developing and commercializing novel drugs to alleviate patient suffering and improve quality of life. With a strong emphasis on research and development, their pipeline of potential therapies demonstrates a dedication to scientific excellence and improving patient outcomes. Furthermore, RELIEF THERAPEUTICS prioritizes collaboration with key stakeholders, including healthcare professionals, regulatory authorities, and patients, to ensure the highest standards of ethical conduct and patient-centered care.

In which countries and regions is RELIEF THERAPEUTICS Holding primarily present?

RELIEF THERAPEUTICS Holding SA primarily operates in Switzerland.

What significant milestones has the company RELIEF THERAPEUTICS Holding achieved?

RELIEF THERAPEUTICS Holding SA has achieved several significant milestones. Firstly, the company successfully developed and obtained FDA approval for their lead drug candidate, RLF-100, also known as Aviptadil, for the treatment of respiratory distress in COVID-19 patients. Additionally, RELIEF THERAPEUTICS entered into a partnership with NeuroRx, Inc. to advance RLF-100's development and commercialization in the United States. The company also received orphan drug designation from the FDA for RLF-100 to treat Acute Respiratory Distress Syndrome (ARDS). Furthermore, RELIEF THERAPEUTICS has collaborated with prominent medical institutions to conduct clinical trials and expand the application of RLF-100 beyond COVID-19. These achievements position RELIEF THERAPEUTICS as a promising player in the biopharmaceutical industry.

What is the history and background of the company RELIEF THERAPEUTICS Holding?

RELIEF THERAPEUTICS Holding SA is a pharmaceutical company with a rich history and background. Established in the year [insert year], RELIEF THERAPEUTICS has dedicated itself to the research and development of innovative therapies to address various medical conditions. The company has garnered extensive expertise in identifying and advancing novel drug candidates, focusing primarily on diseases with high unmet medical needs. RELIEF THERAPEUTICS has established strategic collaborations and partnerships to further expand its reach and accelerate the development of its pipeline products. With a dedicated team of scientists and professionals, the company strives to provide breakthrough solutions for patients worldwide, aligning with its mission to improve healthcare outcomes globally.

Who are the main competitors of RELIEF THERAPEUTICS Holding in the market?

The main competitors of RELIEF THERAPEUTICS Holding SA in the market are other pharmaceutical companies operating in the same therapeutic areas. It is important to note that the competitive landscape may vary depending on the specific product or indication.

In which industries is RELIEF THERAPEUTICS Holding primarily active?

RELIEF THERAPEUTICS Holding SA is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of RELIEF THERAPEUTICS Holding?

The business model of RELIEF THERAPEUTICS Holding SA focuses on the development of innovative therapeutics for various medical conditions. The company primarily specializes in the field of neurology and aims to provide relief to patients suffering from debilitating diseases. RELIEF THERAPEUTICS Holding SA leverages its expertise in drug development and strategic partnerships to advance its pipeline of promising therapeutic candidates. By prioritizing research and innovation, the company aims to address unmet medical needs and improve the quality of life for patients. Through its dedication to discovering novel treatments, RELIEF THERAPEUTICS Holding SA aims to contribute significantly to the healthcare industry.

What is the P/E ratio of RELIEF THERAPEUTICS Holding 2024?

The RELIEF THERAPEUTICS Holding P/E ratio is -2,271.48.

What is the P/S ratio of RELIEF THERAPEUTICS Holding 2024?

The RELIEF THERAPEUTICS Holding P/S ratio is 0.57.

What is the AlleAktien quality score of RELIEF THERAPEUTICS Holding?

The AlleAktien quality score for RELIEF THERAPEUTICS Holding is 3/10.

What is the revenue of RELIEF THERAPEUTICS Holding 2024?

The expected RELIEF THERAPEUTICS Holding revenue is 44.15 M CHF.

How high is the profit of RELIEF THERAPEUTICS Holding 2024?

The expected RELIEF THERAPEUTICS Holding profit is -11,123.97 CHF.

What is the business model of RELIEF THERAPEUTICS Holding

RELIEF THERAPEUTICS Holding SA is a Swiss biotech company specializing in the development of drugs for the treatment of neurological and inflammatory diseases. It was founded in 2016 and has been listed on the Swiss stock exchange SIX since 2019. The activities of RELIEF THERAPEUTICS include several areas, from research and development of new drugs to the marketing of already approved products. The company has an internationally experienced team of researchers, developers, and experts focusing on the identification and development of innovative substances. RELIEF THERAPEUTICS focuses on the development of therapies for the treatment of inflammatory and autoimmune diseases, particularly Crohn's disease, autism, multiple sclerosis, and respiratory diseases such as asthma and COPD. The company has several promising products in its pipeline, currently in various stages of clinical trials. One of the key products of RELIEF THERAPEUTICS is RLF-100 (Aviptadil), currently in clinical development for the treatment of COVID-19. RLF-100 is a synthetic peptide molecule capable of reducing the concentration of the pro-inflammatory molecule tumor necrosis factor-alpha, thereby improving lung function and oxygen uptake. Another important product of RELIEF THERAPEUTICS is Atexakin alfa (RLF-1002), a synthetic peptide molecule in development for the treatment of Crohn's disease and other inflammatory bowel diseases. Atexakin alfa targets the interleukin-6 signaling pathway, which plays a crucial role in the development of inflammation. Furthermore, RELIEF THERAPEUTICS is working on the development of a novel treatment for autism. The company has partnered with biotech company Neurimmune to develop antibodies against the protein C4A, believed to play a significant role in the development of autism. Another important business area for RELIEF THERAPEUTICS is the licensing of already approved products. The company has entered into an agreement with Swiss biotech company Altavant Sciences to license the drug Roxybond, used for pain treatment. Overall, RELIEF THERAPEUTICS has a promising portfolio of products and developments in various medical fields. Through consistent investment in research and development and collaboration with top-notch partners and experts, the company aims to further strengthen its position as a leading provider of innovative therapies.

What is the RELIEF THERAPEUTICS Holding dividend?

RELIEF THERAPEUTICS Holding pays a dividend of 0 CHF distributed over payouts per year.

How often does RELIEF THERAPEUTICS Holding pay dividends?

The dividend cannot currently be calculated for RELIEF THERAPEUTICS Holding or the company does not pay out a dividend.

What is the RELIEF THERAPEUTICS Holding ISIN?

The ISIN of RELIEF THERAPEUTICS Holding is CH0100191136.

What is the RELIEF THERAPEUTICS Holding WKN?

The WKN of RELIEF THERAPEUTICS Holding is A1H80W.

What is the RELIEF THERAPEUTICS Holding ticker?

The ticker of RELIEF THERAPEUTICS Holding is RLF.SW.

How much dividend does RELIEF THERAPEUTICS Holding pay?

Over the past 12 months, RELIEF THERAPEUTICS Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RELIEF THERAPEUTICS Holding is expected to pay a dividend of 0 CHF.

What is the dividend yield of RELIEF THERAPEUTICS Holding?

The current dividend yield of RELIEF THERAPEUTICS Holding is .

When does RELIEF THERAPEUTICS Holding pay dividends?

RELIEF THERAPEUTICS Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RELIEF THERAPEUTICS Holding?

RELIEF THERAPEUTICS Holding paid dividends every year for the past 0 years.

What is the dividend of RELIEF THERAPEUTICS Holding?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is RELIEF THERAPEUTICS Holding located?

RELIEF THERAPEUTICS Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von RELIEF THERAPEUTICS Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RELIEF THERAPEUTICS Holding from 9/9/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did RELIEF THERAPEUTICS Holding pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of RELIEF THERAPEUTICS Holding in the year 2023?

In the year 2023, RELIEF THERAPEUTICS Holding distributed 0 CHF as dividends.

In which currency does RELIEF THERAPEUTICS Holding pay out the dividend?

The dividends of RELIEF THERAPEUTICS Holding are distributed in CHF.

All fundamentals about RELIEF THERAPEUTICS Holding

Our stock analysis for RELIEF THERAPEUTICS Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RELIEF THERAPEUTICS Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.